Our Pricing

Understanding the Wegovy Dose Equivalent to Mounjaro for UK Patients

Finding the correct wegovy dose equivalent to mounjaro is essential for patients considering switching between these weight loss treatments in the UK. While both medications are highly effective GLP-1 receptor agonists, they contain different active ingredients—semaglutide in Wegovy and tirzepatide in Mounjaro—meaning direct milligram-to-milligram equivalence doesn't exist. However, clinical evidence allows UK prescribers to identify comparable therapeutic doses that deliver similar weight loss outcomes, enabling cost-effective switches subject to prescriber approval.

What Is the Wegovy Dose Equivalent to Mounjaro Based on Clinical Evidence?

Determining the wegovy dose equivalent to mounjaro requires understanding both medications' efficacy profiles rather than simple dose conversion. Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist, whilst Wegovy (semaglutide) is a selective GLP-1 receptor agonist. In the SURPASS-2 trial, tirzepatide 15mg demonstrated average weight loss of 12.4kg over 40 weeks, whilst the STEP 1 trial showed semaglutide 2.4mg achieved average weight loss of 14.9% body weight over 68 weeks [1].

From a therapeutic equivalence perspective, UK prescribers generally consider Wegovy 2.4mg (the maximum maintenance dose) to provide comparable weight loss outcomes to Mounjaro 10mg or 12.5mg doses. However, individual response varies significantly, and some patients on Mounjaro 15mg may require careful monitoring when switching to ensure maintained efficacy. The decision must always be made by a qualified UK prescriber following clinical assessment, taking into account your current dose, weight loss progress, and tolerance profile [2].

How to Switch from Mounjaro to Wegovy Dose Equivalent Safely in the UK

Switching to the wegovy dose equivalent to mounjaro requires a structured approach overseen by a UK-registered prescriber. Most patients transitioning from Mounjaro to Wegovy will restart the Wegovy dose escalation schedule from 0.25mg weekly, even if they were on higher Mounjaro doses. This gradual titration minimises gastrointestinal side effects—the most common adverse events with GLP-1 therapies—and allows your body to adjust to the new medication [3].

The typical Wegovy escalation follows a monthly step-up: 0.25mg for 4 weeks, then 0.5mg, 1mg, 1.7mg, and finally 2.4mg maintenance dose. If you're currently on Mounjaro 10mg or above, your prescriber may monitor your weight loss trajectory closely during the switch to ensure you maintain therapeutic benefit. Some patients may reach equivalent efficacy at Wegovy 1.7mg, whilst others require the full 2.4mg dose. All prescription switches require online clinical assessment by a UK prescriber at Cured Pharmacy, ensuring safety and appropriateness for your individual circumstances.

Timeline for Switching Between Mounjaro and Wegovy Doses

When transitioning to the wegovy dose equivalent to mounjaro, most UK prescribers recommend completing your current Mounjaro dose and starting Wegovy the following week. There's no mandatory washout period required between these GLP-1 medications, but spacing them by 7 days helps distinguish any side effects specific to the new treatment. The full dose escalation to reach Wegovy 2.4mg typically takes 16-20 weeks, during which you'll have regular prescriber check-ins to assess tolerance and efficacy [4].

Cost Savings: Wegovy Dose Equivalent to Mounjaro Pricing at Cured Pharmacy UK

Switching to the wegovy dose equivalent to mounjaro can deliver substantial cost savings for UK patients. At Cured Pharmacy, Wegovy is available from £124.99, with new patients saving £20 off their first order using code Weightlossnew. This represents competitive UK pricing for a treatment that has demonstrated average weight loss of 14.9% body weight in clinical trials [1].

Many UK patients find Wegovy offers better value whilst maintaining comparable efficacy to higher Mounjaro doses. Cured Pharmacy provides transparent upfront pricing before consultation, ensuring you understand the total cost of your weight loss treatment. All Wegovy prescriptions require completion of a free online clinical assessment by our UK-registered prescribers, typically completed in under 3 minutes, with discreet next-day delivery available across the UK.

Clinical Efficacy: Comparing Wegovy Dose Equivalent to Mounjaro Outcomes

When evaluating the wegovy dose equivalent to mounjaro, clinical trial data provides the most reliable comparison. The STEP programme trials demonstrated that semaglutide 2.4mg (Wegovy) produced average weight loss of 14.9% body weight over 68 weeks, with 83.5% of participants achieving ≥5% weight loss [1]. In comparison, the SURPASS-2 trial showed tirzepatide 15mg delivered average weight loss of 12.4kg, with dose-dependent efficacy across the 5mg, 10mg, and 15mg strengths [2].

From a practical UK prescribing perspective, patients on Mounjaro 10mg or 12.5mg often achieve similar weight loss outcomes when switched to Wegovy 2.4mg. However, those on Mounjaro 15mg—the highest licensed dose—may experience slightly reduced efficacy with the switch, though many still achieve their weight loss goals. Individual response varies based on adherence, lifestyle factors, and metabolic differences. Your UK prescriber will monitor your progress closely during the transition to ensure you're achieving optimal outcomes with the wegovy dose equivalent to mounjaro suitable for your needs.

Weight Loss Trajectory After Switching to Wegovy Dose Equivalent

Most patients transitioning to the wegovy dose equivalent to mounjaro maintain their weight loss trajectory once they reach the 2.4mg maintenance dose. During the 16-20 week escalation period, weight loss may plateau temporarily, but typically resumes once therapeutic dosing is achieved. UK prescribers recommend maintaining consistent healthy eating patterns and physical activity throughout the switch to optimise outcomes. If weight loss stalls for more than 12 weeks at the maximum Wegovy dose, your prescriber may reassess your treatment plan [3].

Side Effects: What to Expect with Wegovy Dose Equivalent to Mounjaro

Understanding potential side effects when switching to the wegovy dose equivalent to mounjaro helps UK patients prepare for the transition. Both medications share a similar side effect profile, as they're both GLP-1 receptor agonists. The most common adverse events include nausea (reported by 44% of Wegovy users in STEP trials), diarrhoea, constipation, vomiting, and abdominal discomfort, typically most pronounced during dose escalation phases [1].

Patients switching from Mounjaro to Wegovy often report that starting the Wegovy escalation from 0.25mg—even if they tolerated higher Mounjaro doses—helps minimise gastrointestinal symptoms. The gradual titration allows your digestive system to adapt to semaglutide's mechanism of action. Most side effects are mild to moderate and diminish over 4-8 weeks at each dose level. Staying well-hydrated, eating smaller meals, and avoiding high-fat foods can help manage symptoms during the transition to your wegovy dose equivalent to mounjaro.

Who Should Consider Switching to Wegovy Dose Equivalent to Mounjaro?

Identifying whether the wegovy dose equivalent to mounjaro is right for you depends on several clinical and practical factors. UK patients currently on Mounjaro 5mg, 7.5mg, 10mg, or 12.5mg who are seeking more cost-effective treatment whilst maintaining weight loss efficacy are often excellent candidates for switching. Those experiencing supply issues with Mounjaro may also benefit from transitioning to Wegovy, which has demonstrated more consistent UK availability in recent months [4].

However, patients on Mounjaro 15mg who have achieved exceptional weight loss outcomes (>20% body weight reduction) may wish to continue their current treatment, as the higher tirzepatide dose may offer superior efficacy for some individuals. Your UK prescriber will assess your current weight loss trajectory, tolerance profile, medical history, and treatment goals during your clinical consultation at Cured Pharmacy. All switches require prescriber approval and ongoing monitoring to ensure safety and efficacy. Patients with a history of pancreatitis, medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2 require careful evaluation before starting either medication.

Medical Assessment Required for Wegovy Dose Equivalent Prescribing

Before switching to the wegovy dose equivalent to mounjaro, UK regulations require a comprehensive clinical assessment by a registered prescriber. At Cured Pharmacy, our online consultation takes under 3 minutes and covers your current medication, dose, weight loss progress, side effects, medical conditions, and treatment goals. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) and clinical team review every assessment to ensure Wegovy is safe and appropriate for your individual circumstances. This regulatory requirement protects patient safety and ensures optimal treatment outcomes.

Scientific References

1. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., ... & SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
3. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., ... & Lingvay, I. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. [accessed 15 August 2026]
4. Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., ... & STEP 5 Study Group. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083-2091. [accessed 15 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.